Equities research analysts expect Inogen Inc (NASDAQ:INGN) to post $79.82 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Inogen’s earnings, with the highest sales estimate coming in at $81.98 million and the lowest estimate coming in at $76.74 million. Inogen posted sales of $64.12 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 24.5%. The business is expected to report its next quarterly earnings report on Thursday, August 2nd.
On average, analysts expect that Inogen will report full-year sales of $320.48 million for the current year, with estimates ranging from $317.11 million to $325.30 million. For the next fiscal year, analysts expect that the firm will post sales of $380.25 million per share, with estimates ranging from $369.04 million to $392.17 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Inogen.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Monday, April 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.19. Inogen had a return on equity of 14.81% and a net margin of 9.36%. The company had revenue of $79.05 million during the quarter, compared to analysts’ expectations of $63.86 million. During the same period last year, the firm posted $0.27 earnings per share. The business’s revenue was up 50.6% on a year-over-year basis.
A number of analysts have recently issued reports on INGN shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Inogen in a research report on Tuesday, March 27th. ValuEngine raised Inogen from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 5th. BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 6th. Finally, Piper Jaffray Companies set a $145.00 price objective on Inogen and gave the company a “buy” rating in a research report on Saturday, April 14th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the stock. Inogen currently has a consensus rating of “Buy” and a consensus target price of $178.00.
INGN opened at $186.06 on Monday. Inogen has a 12-month low of $89.01 and a 12-month high of $194.23. The company has a market capitalization of $3.99 billion, a PE ratio of 142.03, a price-to-earnings-growth ratio of 4.74 and a beta of 1.10.
In related news, insider Scott Wilkinson sold 9,198 shares of Inogen stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $170.35, for a total transaction of $1,566,879.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alison Bauerlein sold 5,000 shares of Inogen stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $180.69, for a total value of $903,450.00. Following the sale, the chief financial officer now directly owns 9,161 shares of the company’s stock, valued at $1,655,301.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 58,589 shares of company stock valued at $10,581,530. 5.29% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Inogen during the 1st quarter worth approximately $178,000. Highbridge Capital Management LLC acquired a new stake in Inogen during the 1st quarter worth approximately $217,000. Suntrust Banks Inc. acquired a new stake in Inogen during the 4th quarter worth approximately $223,000. Jane Street Group LLC acquired a new stake in Inogen during the 4th quarter worth approximately $243,000. Finally, Raymond James & Associates acquired a new stake in Inogen during the 4th quarter worth approximately $244,000. 97.86% of the stock is owned by institutional investors and hedge funds.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Get a free copy of the Zacks research report on Inogen (INGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.